Wednesday, October 03, 2018 7:41:23 AM
Posted by ABMN Staff on Oct 3rd, 2018 // No Comments
Viewray logoViewray (NASDAQ:VRAY)‘s stock had its “buy” rating restated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday. They currently have a $13.00 target price on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 36.84% from the company’s current price.
The analysts wrote, “We reiterate our Overweight rating on shares of VRAY and our 12-month price target of $13. VRAY has succeeded in bringing an MRI linear accelerator (linac) to the market when its larger competitors could not. VRAY’s differentiated technology has the potential to change radiation therapy longer term, but VRAY’s commercial launch is only in its infancy. Positive early clinical data are driving physician interest, but the price of the system comes at a significant premium (~50%) to existing linacs. VRAY, like many small capital equipment companies, comes with a good amount of risk, but we think the momentum is building.””
https://www.americanbankingnews.com/2018/10/03/viewray-vray-stock-rating-reaffirmed-by-cantor-fitzgerald.html
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM